Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. - Harbeck, N.; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; et al. (Annals of Oncology, 2026)